Scrip's Stock Tracker February 2010
This article was originally published in Scrip
Executive Summary
Talk of dividends being under threat at companies such as Bristol-Myers Squibb, Pfizer and Lilly, combined with the increased need across industry to scale back on costs and the ever-present – and growing – pressure to keep pipelines strong and attractive, made for a lacklustre month on the equities markets for the leading pharma stocks.